NuVasive Announces Conference Call and Webcast Regarding Reimbursement
November 25 2009 - 7:30AM
PR Newswire (US)
SAN DIEGO, Nov. 25 /PRNewswire-FirstCall/ -- NuVasive, Inc.
(NASDAQ: NUVA), a medical device company focused on developing
products for minimally disruptive surgical treatments for the
spine, announced today that it will host a conference call on
Monday, November 30, 2009, at 5:30 p.m. ET / 2:30 p.m. PT. The
conference call will focus on current issues relative to
reimbursement for the Company's products and will include comments
from management followed by a short question and answer session.
The dial-in numbers are 1-877-407-4018 for domestic callers and
1-201-689-8471 for international callers. A live webcast of the
conference call will be available online from the investor
relations page of the Company's corporate website at
http://www.nuvasive.com/. As a reminder, management will be
presenting at the 21st Annual Piper Jaffray Health Care Conference
at the New York Palace in New York, New York, on Wednesday,
December 2, 2009, at 10:00 a.m. ET. and at the J.P. Morgan SMid Cap
Conference at the J.P. Morgan Conference Center in New York, New
York, on Thursday, December 3, 2009, at 1:30 p.m. ET. A live
webcast of both presentations will be available online from the
investor relations page of the Company's corporate website at
http://www.nuvasive.com/. After Monday's live webcast, the call
will remain available on NuVasive's website,
http://www.nuvasive.com/, through December 30, 2009. In addition, a
telephonic replay of the call will be available until December 14,
2009. The replay dial-in numbers are 1-877-660-6853 for domestic
callers and 1-201-612-7415 for international callers. Please use
account number 3055 and conference ID number 338644. About NuVasive
NuVasive is a medical device company focused on the design,
development, and marketing of products for the surgical treatment
of spine disorders. The Company's product portfolio is focused
primarily on the $4.6 billion U.S. spine implant market.
Additionally, the Company has expanded into the $1.5 billion global
biologics market, the $1.5 billion international market, and is
developing products for the emerging motion preservation market.
NuVasive's principal product offering is based on its Maximum
Access Surgery, or MAS® platform. The MAS platform combines four
categories of products that collectively minimize soft tissue
disruption during spine surgery with maximum visualization and
safe, easy reproducibility for the surgeon: NeuroVision®, a
proprietary software-driven nerve avoidance system; MaXcess®, a
unique split-blade retractor system; a wide variety of specialized
implants; and several biologic fusion enhancers. MAS significantly
reduces surgery time and returns patients to activities of daily
living much faster than conventional approaches. Having redefined
spine surgery with the MAS platform's lateral approach, known as
eXtreme Lateral Interbody Fusion, or XLIF®, NuVasive has built an
entire spine franchise. With nearly 50 products today spanning
lumbar, thoracic and cervical applications, the Company will
continue to expand and evolve its offering predicated on its
R&D focus and dedication to outstanding service levels
supported by a culture of Absolute Responsiveness®. NuVasive
cautions you that statements included in this press release that
are not a description of historical facts are forward-looking
statements that involve risks, uncertainties, assumptions and other
factors which, if they do not materialize or prove correct, could
cause NuVasive's results to differ materially from historical
results or those expressed or implied by such forward-looking
statements. The potential risks and uncertainties that could cause
actual growth and results to differ materially include, but are not
limited to: the uncertain process of seeking regulatory approval or
clearance for NuVasive's products or devices, including risks that
such process could be significantly delayed; the risk that
government or private payers may deny reimbursement to hospitals
for use of the Company's products; the risk that NuVasive may be
unsuccessful in its efforts to convince government or private
payers to provide adequate reimbursement for its products; the
possibility that the FDA may require significant changes to
NuVasive's products or clinical studies; the risk that products may
not perform as intended and may therefore not achieve commercial
success; the risk that competitors may develop superior products or
may have a greater market position enabling more successful
commercialization; the risk that additional clinical data may call
into question the benefits of NuVasive's products to patients,
hospitals and surgeons; and other risks and uncertainties more
fully described in NuVasive's press releases and periodic filings
with the Securities and Exchange Commission. NuVasive's public
filings with the Securities and Exchange Commission are available
at http://www.sec.gov/. NuVasive assumes no obligation to update
any forward-looking statement to reflect events or circumstances
arising after the date on which it was made. Contact: Investors:
Michael J. Lambert Patrick F. Williams Vice President, Finance
& Investor EVP & Chief Financial Officer Relations
NuVasive, Inc. NuVasive, Inc. 858-909-1998 858-638-5511 Media:
Jason Rando The Ruth Group 646-536-7025 DATASOURCE: NuVasive, Inc.
CONTACT: Michael J. Lambert, EVP & Chief Financial Officer,
+1-858-909-1998; Investors: Patrick F. Williams, Vice President,
Finance & Investor Relations, +1-858-638-5511, both of
NuVasive, Inc., ; Media: Jason Rando of The Ruth Group,
+1-646-536-7025, or , for NuVasive, Inc. Web Site:
http://www.nuvasive.com/
Copyright